Clinical Trial Update: A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease [Phase 1, Phase 2]

View source ↗

Summary

AbbVie conducted a Phase 1/2 study of AGN-242428 and AGN-231868 in dry eye disease; the trial has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• AGN-231868
• AGN-242428

Snippet

Sponsor: AbbVie | Conditions: Dry Eye Disease, Dry Eye Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-05-20